Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON7 bevacizumab plus carboplatin/paclitaxel in ovarian, fallopian tube, or primary peritoneal cancer
ACTRN12607000188437Phase 3Active, not recruiting
- Sponsor
- Medical Research Council
- Start
- Dec 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, carboplatin and paclitaxel in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Medical Research Council. Primary endpoint: Progression-free survival. Started Dec 2006; status: active, not recruiting.
02
Drugs
bevacizumabcarboplatinpaclitaxel
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12607000188437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000188437.